Serum concentration of IL-17, IL-23 and TNF-α among patients with chronic spontaneous urticaria: Association with disease activity and autologous serum skin test

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 4, 2014, Pages 469-474

  Atwa, M A ^a   Emara, A S ^b   Youssef, N ^a   Bayoumy, N M ^c  

^a Suez Canal University Faculty of Medicine   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 23; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; AUTOLOGOUS SERUM SKIN TEST; CHRONIC SPONTANEOUS URTICARIA; CHRONIC URTICARIA; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SKIN TEST; BLOOD; CASE CONTROL STUDY; PROCEDURES; URTICARIA;

CASE-CONTROL STUDIES; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; SKIN TESTS; TUMOR NECROSIS FACTOR-ALPHA; URTICARIA;

EID: 84899428887     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12124     Document Type: Article

References (49)

1. Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A,. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1. Allergy 2011; 66: 317-330.
2. Hide M, Francis D, Grattan C, et al,. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328: 1599-604.
3. Niimi N, Francis D, Kermani F, et al,. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996; 106: 1001-1006.
4. Fiebiger E, Maurer D, Holub H, et al. Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995; 96: 2606-2612.
5. Tong L, Balakrishnan G, Kochan J, et al,. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997; 99: 461-465.
6. Kikuchi Y, Kaplan A,. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 2001; 107: 1056-1062.
7. Konstantinou G, Asero R, Maurer M, et al,. EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy 2009; 64: 1256-1268.
8. Sabroe RA, Grattan CE, Francis DM, et al,. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999; 140: 446-452.
9. Grattan CEH,. The urticaria spectrum. Recognition of clinical patterns can help management. Clin Exp Dermatol 2004; 29: 217-221.
10. Elias J, Boss E, Kaplan AP,. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol 1986; 1: 914-918.
11. Ying S, Kikuchi Y, Meng Q, et al,. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002; 109: 694-700.
12. Ferrer M, Luquin E, Sanchez-Ibarrola A, et al,. Secretion of cytokines, histamine and leukotrienes in chronic urticaria. Int Arch Allergy Immunol 2002; 129: 254-260.
13. Cua DJ, Sherlock J, Chen Y, et al,. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748.
14. Langrish CL, Chen Y, Blumenschein WM, et al,. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
15. Murphy CA, Langrish CL, Chen Y, et al,. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198: 1951-1957.
16. Aggarwal S, Ghilardi N, Xie MH, et al,. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-1914.
17. Harrington LE, Hatton RD, Mangan PR, et al,. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
18. Liang SC, Tan XY, Luxenberg DP, et al,. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-2279.
19. Bettelli E, Oukka M, Kuchroo VK,. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8: 345-350.
20. Ouyang W, Kolls JK, Zheng Y,. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454-467.
21. Wilson NJ, Boniface K, Chan JR, et al,. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-957.
22. Chen Z, Tato CM, Muul L, et al,. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum 2007; 56: 2936-2946.
23. Mangan PR, Harrington LE, O'Quinn DB, et al,. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441: 231-234.
24. Rouvier E, Luciani MF, Matte'i MG, et al,. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a Herpesvirus saimiri gene. J Immunol 1993; 150: 5445-5456.
25. Yao Z, Fanslow WC, Seldin MF, et al,. Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995; 3: 811-821.
26. Fujino S, Andoh A, Bamba S, et al,. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70.
27. Lock C, Hermans G, Pedotti R, et al,. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 500-508.
28. Teunissen MB, Koomen CW, de Waal Malefyt R, et al,. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111: 645-649.
29. Ziolkowska M, Koc A, Luszczykiewicz G, et al,. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2002; 164: 2832-2838.
30. Trinchieri G, Pflanz S, Kastelein RA,. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2005; 19: 641-644.
31. Harrington LE, Mangan PR, Weaver CT,. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006; 18: 349-356.
32. Walsh LJ, Trinchieri G, Waldorf HA, et al,. Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991; 88: 4220-4224.
33. 2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417-1426.
34. Statistical package for Social Sciences, Version 17, SPSS Inc., Chicago, IL, USA.
35. Greaves MW,. Chronic urticaria. J Allergy Clin Immunol 2000; 105: 664-672.
36. Caproni M, Volpi W, Macchia D, et al,. Infiltrating cells and related cytokines in lesional skin of patients with chronic idiopathic urticaria and positive autologous serum skin test. Exp Dermatol 2003; 12: 621-628.
37. Kryczek I, Bruce AT, Gudjonsson JE, et al,. Induction of IL-17+ T cell trafficking and development by IFN-γ: mechanism and pathological relevance in psoriasis. J Immunol 2008; 181: 4733-4741.
38. Daschner A, Rodero M, De Frutos C, et al,. Different serum cytokine levels in chronic vs. acute Anisakis simplex sensitization-associated urticaria. Parasite Immunol 2011; 33: 357-362.
39. Azor MH, dos Santos JC, Futata EA, et al,. Statin effects on regulatory and proinflammatory factors in chronic idiopathic urticaria. Clin Exp Immunol 2011; 166: 291-298.
40. Beyer BM, Ingram R, Ramanathan L, et al,. Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody. J Mol Biol 2008; 382: 942-955.
41. Brentano F, Ospelt C, Stanczyk J, et al,. Abundant expression of the interleukin (IL) 23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis. Ann Rheum Dis 2008; 68: 143-150.
42. Shen H, Xia L, Lu J, Xiao W,. Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand J Rheumatol 2011; 40: 217-220.
43. McGeachy MJ, Chen Y, Tato CM, et al,. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009; 10: 314-324.
44. Iwakura Y, Ishigame H,. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116: 1218-1222.
45. Tillie-Leblond I, Gosset P, Janin A, et al,. Tumor necrosis factor-alpha release during systemic reaction in cold urticaria. J Allergy Clin Immunol 1994; 93: 501-509.
46. Hermes B, Prochazka AK, Haas N, et al,. Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol 1999; 103: 307-314.
47. Piconi S, Trabattoni D, Iemoli E, et al,. Immune profiles of patients with chronic idiopathic urticaria. Int Arch Allergy Immunol 2002; 128: 59-66.
48. Dos Santos J, Azor M, Nojima V, et al,. Increased circulating pro-inflammatory cytokines and imbalanced regulatory T-cell cytokines production in chronic idiopathic urticaria. Int Immunopharmacol 2008; 8: 1433-1440.
49. Tedeschi A, Lorini M, Suli C, Asero R,. No evidence of tumor necrosis factor-α release in blood of patients with chronic urticaria. Allergy 2006; 61: 510-511.